LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On September 15, 2022, BioLine announced that Kreos Capital VII Aggregator SCSP will provide the Company with term loans in an aggregate principal amount of up to $40 million.
On September 19, 2022, BioLine announced a registered direct offering of approximately 14 million American Depositary Shares (“ADSs” or “shares”) and warrants to purchase ADSs for a combined price of $1.10 per ADS and associated warrant.
On this news, the Company’s share price fell 33% to close at $1.02 per share on September 19, 2022.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased BioLine securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
